Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
A prospective non-interventional study in Russia evaluates clinical outcomes of Ribociclib (Risarg) combined with endocrine therapy or chemo…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer [Phase 2]
Phase 2 study updating SKB264 with or without KL-A167 for recurrent/metastatic HER2-negative breast cancer, including triple-negative and HR…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating trastuzumab deruxtecan, alone or in combination with anastrozole, for early-stage HER2-low, hormone rece…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer [Phase 1]
BeOne Medicines is conducting a Phase 1 trial evaluating BGB-21447, a Bcl-2 inhibitor, in combination regimens for adults with hormone recep…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) [Phase 2]
Phase 2 clinical trial update evaluating preoperative pembrolizumab plus radiation therapy in breast cancer, including triple-negative and H…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy [Phase 3]
A Phase 3 clinical trial comparing sacituzumab govitecan with physician's choice in HR+/HER2- metastatic breast cancer after endocrine thera…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating adaptive therapy with capecitabine for metastatic estrogen receptor-positive, HER2-negative breast ca…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of combining camizestrant with ribociclib in hormone receptor-positive breast canc…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update on Invikafusp alfa in combination with sacituzumab govitecan in adults with advanced solid tumors, including triple-ne…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. [Phase 2]
A Phase 2 clinical trial evaluating abemaciclib in combination with endocrine therapy for older patients with breast cancer is currently rec…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone Therapy
A clinical trial update describes the development of a remote monitoring model for patients with HR-positive, HER2-negative breast cancer tr…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers [Phase 2]
A Phase 2 clinical trial update for SC-101 in nectin-4 amplified cancers, including triple-negative breast cancer and hormone receptor-posit…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Comparison of the Breast Tumor Microenvironment
This document provides an update on a clinical trial studying the breast tumor microenvironment in breast cancer subtypes, including triple-…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy [Phase 2]
Phase 2 neoadjuvant breast cancer trial at Fudan University Shanghai Cancer Center evaluating a precision-platform therapy; the study is cur…
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib [Phase 2]
This Phase 2 trial update describes using circulating tumor DNA in the blood to guide which patients with HR-positive, HER2-negative metasta…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) [Phase 2]
A Phase 2 neoadjuvant trial is evaluating chemotherapy in combination with anlotinib and Benmelstobart for HR+/HER2- breast cancer; the stud…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer
Clinical trial update describes establishing molecular profiling to guide individual treatment decisions in early breast cancer. The study i…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer [NA]
This clinical trial update describes a study to assess whether prolonged overnight fasting and/or exercise affects fatigue and other patient…
-
CLINICAL_TRIALS research · 2025-07-22Clinical Trial Update: Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer [NA]
A clinical trial update evaluating whether a fasting-mimicking diet can augment neoadjuvant chemotherapy for hormone-receptor-positive breas…
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Real-world study evaluating post-resistance treatment strategies after CDK4/6 inhibitors, PIK3CA inhibitors, or trastuzumab deruxtecan in ad…
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the body's response to exercise and a plant-based diet in overweight postmen…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]
Phase III trial evaluating ESG401 for locally advanced or metastatic HR+/HER2- breast cancer; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients [Phase 2]
A Phase II clinical trial is evaluating HLX22 in combination with trastuzumab deruxtecan for HER2-low, hormone receptor-positive breast canc…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy [Phase 2]
This entry notes a Phase 2 clinical trial evaluating preoperative elacestrant in combination with PULSAR radiotherapy for hormone receptor-p…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial update for BGB-43395, evaluating it alone or in combination therapies in Chinese participants with HR+/HER2- breast c…